Polycythemia vera

Polycythemia vera (PV) is an acquired myeloproliferative disorder characterized by an elevated absolute red blood cell mass caused by uncontrolled red blood cell production, frequently associated with uncontrolled white blood cell and platelet production.

Hepatitis

Inflammation of the liver.


Total: 2

                       


(per page)
PMID (PMCID)
27150448
 OTHER
Development of Hypercalcemia in a Patient Receiving Peginterferon alfa-2a Therapy for Polycythemia Vera.
Karne S, Mainor CB, Baer MR.
Pharmacotherapy. 2016;36(6):e54-e57.
Peginterferon alfa-2a (PEG-IFN alfa-2a) is commonly used to treat hepatitis C virus infection and is also being used increasingly to treat myeloproliferative neoplasms including polycythemia vera.
24067929
 FEMALE Middle Aged
Reversible bone marrow aplasia induced by pegylated interferon-alpha-2a therapy in a patient with primary myelofibrosis.
Mainali NR, Bhatt VR, Kedia S, Krishnamurthy J, Wake LM, Akhtari M.
J Oncol Pharm Pract. 2014;20(5):386-92.
Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-945-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported.